Daiichi Sankyo To Buy U3 Pharma Of Germany For $233.5 Million
This article was originally published in PharmAsia News
Daiichi Sankyo says it plans to buy U3 Pharma of Germany for $233.5 million. The German bioventure specializes in antibodies as treatments for cancer. Daiichi's investment is seen as an effort to become a larger player in an area with a potential for high growth. The Japanese firm plans clinical trials of U3 Pharma drugs in Japan, the United States and Europe, drawing on the German company's ties with U.S. biotech Amgen. (Click here for more - a subscription may be required
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.